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incidence
Breast cancer is the most common cancer in women in many
countries, including developing countries. In 2006, the crude
incidence in the European Union was 109.8/100 000, the
mortality was 38.4/100 000 women/year. Since 1990 the
incidence rate has increased 1.5% annually. Due to advances
both in early detection and in adjuvant treatment, mortality
rates from breast cancer have been decreasing steadily in most
western countries since the early 1990s. However, it is still the
leading cause of cancer mortality in women. Approximately 6%
of breast cancers are metastatic at diagnosis with a 5-year
survival rate of 21%. Depending on prognostic factors, in the
worst scenario, up to 30% of node-negative and up to 70% of
node-positive breast cancers will relapse. The prevalence of
metastatic disease is high because many women live with the
disease for several years.
diagnosis
Clinical suspicion must be confirmed by imaging (including
functional imaging); additional information may be provided
by laboratory tests.
Efforts should be made to obtain histopathological
confirmation particularly in the situation of an isolated
metastatic lesion. Biological markers important for treatment
decisions, such as hormonal receptors and HER2 status, should
be evaluated in the metastatic lesion whenever possible.
Potential exceptions are (a) situations where the biopsy
procedure is too risky, (b) the time elapsed between the
primary tumour and the metastatic disease diagnosis is
relatively short or (c) when the results of the biopsy are unlikely
to change the therapeutic attitude (e.g. pre-existent
contraindications for the use of chemotherapy or anti-HER2
therapies).
There is no proven value of routine diagnostic tests
‘screening’ for metastatic disease in asymptomatic patients.
However, the available data are from a time when neither
biological therapy nor efficacious (in terms of local control)
and less invasive loco-regional techniques, such as radiosurgery
for central nervous system (CNS) metastases or radiofrequency
for liver metastases, were available. Additionally, new techniques
are now available, such as magnetic resonance imaging (MRI),
PET scan, PET–CT, circulating tumour cells and others, that
may allow for the detection of very early metastatic disease.
Therefore, new studies are needed to evaluate the role of early
diagnosis of metastatic disease in this new context.
The occurrence of loco-regional recurrence is often
associated with distant spread and such patients should
undergo full staging procedures before undergoing local
treatments.
staging and risk assessment
 Complete history, including:
(i) menopausal status and co-morbidities;
(ii) detailed history of the primary tumour, its biology,
management and status at last follow-up;
(iii) history of recurrent/metastatic disease including
duration, previous sites of involvement, previous
treatments and their effect;
(iv) current symptoms, performance status, socio-
economic background and preferences (Table 1).
 Detailed physical examination.
 Blood tests: complete blood count, liver and renal function
tests, alkaline phosphatase, calcium and, if applicable, specific
tests required for particular treatments such as urinary
protein. The clinical value of tumour markers has not been
well proven; however, their use may be of value to assess the
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efficacy of treatment particularly in patients with non-
measurable disease.
 Chest X-ray or computed tomography (CT), abdominal
ultrasound, CT or MRI should be used to identify visceral
disease.
 Bone scintigraphy, with confirmation of lesions by X-ray/CT/
MRI.
 CT and/or MRI of the CNS should be symptom driven.
 PET/PET–CT may be useful for identifying the site of relapse,
particularly when traditional imaging methods are equivocal
or conflicting. It may also be helpful to identify an isolated
metastatic lesion, since this subset of patients may benefit
from a more aggressive multidisciplinary approach.
 Estrogen and progesterone receptors, HER2 receptors and
proliferation markers of the metastatic lesion should be
obtained, if possible, and particularly if not available on the
primary tumour.
 Cardiac assessments, in particular in HER2(+) patients.
 Circulating tumour cells is still an experimental technique
and should not be used outside a clinical trial.
treatment
local–regional recurrence
Isolated local–regional recurrence should be treated like
a new primary with a curative intent. If feasible, complete
excision of recurrent tumour is recommended. In patients not
exposed to postoperative irradiation, radical radiotherapy to
chest wall and (in most cases) regional lymph node areas
should be given. In those previously irradiated, the value of re-
irradiation is not proven; however, re-irradiation to limited
areas in the chest wall may be applied, after a careful benefit–
risk balance, taking into consideration the duration of
radiation-free period, intensity of post-radiotherapy changes
and the risk of local–regional relapse. Inoperable patients can, if
feasible, undergo radical radiotherapy to chest wall and regional
lymph node areas with boost to macroscopic disease sites.
However, in these patients, primary systemic therapy to
decrease the size of the tumour and render it operable should
be the first choice.
The value of ‘secondary or pseudo-adjuvant’ systemic
treatment is not well proven. The role of ‘secondary or pseudo-
adjuvant’ chemotherapy is a subject of ongoing randomized
studies [II, B].
metastatic disease
 The management of metastatic breast cancer (MBC) should
involve all appropriate specialties in a multi/interdisciplinary
team (medical, radiation, surgical and imaging oncologists,
palliative care specialist, psychosocial support), and patients
should be offered personalized appropriate psychosocial,
supportive and symptom-related interventions as a routine
part of their care.
 There are few proven standards of care in MBC management,
therefore well-designed, independent, prospective
randomized trials are a priority.
 The vast majority of MBC is incurable and hence the main
treatment goal is palliation, with the aim of maintaining/
improving quality of life, and possibly improving survival.
 The realistic treatment goals should be discussed with the
patient and her family from the beginning and the patient
should be encouraged to actively participate in all decisions.
Patients’ preferences should always be taken into account.
 Co-ordination and continuity of care may need to be
facilitated by a specialist breast care nurse or key worker.
 Systemic treatment options for MBC are endocrine therapy,
chemotherapy and biological agents such as trastuzumab,
bevacizumab and lapatinib [I, A] (see Table 1).
 The choice of therapy should be made after consideration of
factors such as: previous therapies and response to them,
disease-free interval, endocrine responsiveness, HER2 status,
tumour burden (defined as number and site of metastases),
menopausal status, biological age and co-morbidities
(including organ dysfunction), performance status, need for
rapid disease/symptom control, socio-economic and
psychological factors, patient’s preference and available
therapies in the patient’s country.
 Patients’ preferences should always be taken into account not
only about treatment options but also methods of treatment
administration (i.v. or oral).
 For the majority of patients, overall survival outcomes from
sequential use of single cytotoxic drugs are equivalent to
combination chemotherapy. The choice between both these
options should primarily take into account the need for
a rapid and significant response and quality of life.
 Duration of each regimen and number of regimens should be
tailored to each individual patient.
 Radiation therapy is an integral part of palliative treatment.
The most common indications for palliative radiotherapy
include:
 Bone metastases that are painful or carry a risk of fractures
and/or neurological complications (radiotherapy options
include ‘limited field’ external beam irradiation, hemi-body
irradiation and application of radioactive ‘bone-seeking’
isotopes);
Table 1. Factors to consider in risk assessment and treatment decision
making for MBC
Disease-related factors Patient-related factors
Disease-free interval Patient’s preferences
Previous therapies and
response
Biological age
Biological factors (hormonal
receptors, HER2)
Menopausal status
Tumour burden (number
and site of metastases)
Co-morbidities and
performance status
Need for rapid disease/
symptom control
Socio-economic and
psychological factors
Available therapies in the
patient’s country
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 Brain metastases (several series have shown that, in
patients with single or a few metastatic foci, stereotactic
radiosurgery can be used with equally good local control
and less side-effects than whole brain radiotherapy);
 Painful or fungating soft tissue masses.
 For limited metastatic presentations surgery or radical
radiotherapy may be considered.
 Bisphosphonates should be used for the treatment of
hypercalcaemia and clinically evident bone metastases (to
palliate symptoms and decrease risk of bone events) [I, A].
The timing and optimal duration of bisphosphonates are
unknown. The choice of drugs, their timing, optimal
duration, methods of administration and side-effects have
significant consequences for a patient’s life-style especially in
terms of their ability to adhere to treatment. Monitoring of
acceptability and adherence is crucial, and choice where
possible should be offered.
patients with luminal-type breast
cancer (hormone receptor-positive
breast cancer, irrespective of HER2
status)
 Endocrine therapy is the preferred option except when
clinically aggressive disease mandates a quicker response or if
there are doubts regarding the endocrine responsiveness of
the tumour. Available endocrine agents are listed in Table 2.
 The choice of endocrine agent should be individualized
according to the safety profile, patient’s co-morbidities and
tumour biology.
 Apart from combination of tamoxifen with ovarian
suppression in premenopausal patients there is no rationale
for the use of combination hormonal therapies.
 The value of maintenance with hormonal treatment after
chemotherapy has not been confirmed by controlled clinical
studies, but is a reasonable approach.
 Concomitant chemo-hormonal therapy is discouraged.
 In the case of HER2 overexpression/amplification, addition of
anti-HER2 therapies to hormonal treatment is beneficial.
premenopausal patients
If no prior adjuvant tamoxifen or if discontinued for >12
months: tamoxifen with ovarian ablation (luteinizing hormone
releasing hormone analogue or surgery) is the preferred option
[I, B]. Otherwise, third-generation aromatase inhibitors may be
considered after or concomitantly with ovarian ablation.
Further treatment lines (in patients who had undergone
ovarian ablation/suppression) do not differ from those used in
the postmenopausal population (as described below).
postmenopausal patients
If no prior adjuvant third-generation aromatase inhibitors
(anastrozole, letrozole, exemestane) or if discontinued for >12
months these are the preferred options since they have
consistently shown superior results to tamoxifen as first-line
therapy in terms of response rate, time to progression and, for
letrozole, in 2-year overall survival [II, A]. Caution should be
given to the risk of accelerated bone loss in these patients.
Tamoxifen remains an acceptable first-line therapy. Patients
given tamoxifen should be instructed to avoid use of drugs
modulating the activity of CYP2D6, such as some selective
serotonin reuptake inhibitor antidepressants (paroxetine,
fluoxetine).
Second-line hormone therapy may include tamoxifen, third-
generation aromatase inhibitors (if not previously used),
fulvestrant, megestrol acetate and androgens. No definitive
recommendation can be given for endocrine treatment cascade,
and particularly, the best option after progression on a third-
generation aromatase inhibitor is currently unknown.
Patients with clear evidence of endocrine resistance should be
offered chemotherapy or participation in clinical trials.
patients with ‘triple negative’ breast
cancer (hormone receptor-negative and
HER2-non-overexpressed/
non-amplified breast cancer)
 Patients having hormone receptor-negative tumours are
candidates for cytotoxic chemotherapy. Available agents/
regimens are listed in Table 3.
 The only standard of care with level 1 evidence is the use of
a taxane-based regimen as first-line therapy in patients
progressing after adjuvant anthracycline-based chemotherapy
[I A]. The selection of the best agent/regimen should be
individualized and should take into account the factors listed
in Table 1.
 For the majority of patients, overall survival outcomes from
the sequential use of single cytotoxic drugs are equivalent to
that of combination chemotherapy, with less associated toxicity
and better quality of life. Therefore, in the absence of the need
for a rapid and significant response for symptom control or
life-threatening disease, preference should be given to the
sequential use of single cytotoxic agents. However, very few
randomized clinical trials have correctly addressed this question
Table 2. Available endocrine therapies for MBC
Class of agent
Selective estrogen receptor
modulators
Tamoxifen; toremifene
Estrogen receptor down-regulator Fulvestrant
Luteinizing hormone-releasing
hormone analogues
Goserelin; leuprorelin
Third-generation aromatase
inhibitors
Non-steroidal Anastrozole, letrozole
Steroidal Exemestane
Progestins Medroxyprogesterone acetate;
megestrol acetate
Androgens
Anabolic steroids Nandrolone decanoa
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and there is an urgent need for a well-designed, prospective
randomized trial to compare sequential single-agent with
combination chemotherapy as first-line therapy of MBC.
 There is no standard approach for patients requiring second-
or further-line treatment since there are no data supporting
the superiority of any particular regimen.
 Duration of each regimen and number of regimens should be
tailored to each individual patient. Continuing beyond third-
line may be justified in patients with good performance status
and response to previous chemotherapy.
 High-dose chemotherapy should not be proposed.
 The role of bevacizumab will be discussed in the section on
other biological agents.
patients with HER2-positive
(overexpressed/amplified) breast
cancer
 Patients should be treated with trastuzumab with or without
chemotherapy [II, B].
 Trastuzumab should be offered early to all HER2-positive
MBC patients.
 Cardiac monitoring should be performed before and while on
trastuzumab therapy.
 The bulk of retrospective data and results of the phase III
randomized Trial Beyond Progression show that continuing
trastuzumab after the first disease progression, associated
with a different chemotherapy regimen is superior to the
discontinuation of this agent. With the approval of lapatinib
for the treatment of MBC, the question of continuing
trastuzumab or changing to lapatinib at the time of first
progression remains open.
 Lapatinib has shown a significant increase in time to
progression in combination with capecitabine in patients
progressing after trastuzumab.
 Addition of anti-HER2 agents (trastuzumab and lapatinib) to
endocrine therapy allows for prolongation of progression-free
survival (PFS) and may be a viable option in patients with
ER/PgR-positive and HER2-positive tumours.
 Other anti-HER2 or pan-anti-HER agents, such as
pertuzumab and HKI-272, are currently under investigation
as are combinations of trastuzumab with other biological
agents with or without chemotherapy to tackle the problem
of resistance to trastuzumab.
other biological agents
 Bevacizumab, an anti-angiogenic agent, has been approved by
the FDA and the EMEA for use in combination with
paclitaxel as first-line treatment of MBC after showing
a benefit of 6 months in PFS in the ECOG 2100 study.
However, in two other randomized phase III trials, the
AVADO and RIBBON studies, the benefit of bevacizumab in
an unselected breast cancer population was of 1 month in PFS
with no significant benefit in overall survival. Efforts must
continue to be made to clearly identify which patients may
benefit from this expensive therapy.
 Several biological or targeted agents are currently under
active investigation as single agents or in combination.
response evaluation
 Response evaluation is routinely recommended after 2–3
months of endocrine therapy and after two or three cycles
of chemotherapy by clinical evaluation, subjective symptom
evaluation, blood tests and repeating the initially
abnormal radiological examinations with comparative
measurements. However, the interval between assessments
should be tailored to the clinical needs of the patient and to
the aggressiveness of the disease. In the case of clinical
suspicion of progressive disease appropriate tests (imaging
and laboratory) should be performed irrespective of
scheduled examinations, if necessary including areas not
imaged in previous tests.
 Serum tumour markers (CA 15-3) may be helpful in
monitoring response, particularly in the case of not easily
measurable disease, but should not be used as the only
determinant for treatment decision.
 The role of PET/PET–CT in response assessment is still under
investigation.
 Maintenance of a good quality of life is paramount and can
best be achieved with prompt amelioration of symptoms and
side-effects of treatment. Psychometrically sound, well-
validated questionnaires are available to measure patient-
Table 3. Selection of available chemotherapy agents/regimens for MBC
Non-anthracycline-containing
Cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Platinum-based combinations (e.g. cisplatin + 5-fluorouracil)
Capecitabine
Vinorelbine
Gemcitabine
Capecitabine + vinorelbine
Vinorelbine 6 gemcitabine
Oral cyclophosphamide with or without methotrexate (metronomic
chemotherapy)
Anthracycline-containing
Doxorubicin or epirubicin monotherapy (weekly or 3-weekly)
Doxorubicin or epirubicin/cyclophosphamide
Liposomal doxorubicin with or without cyclophosphamide
5-fluorouracil/doxorubicin/cyclophosphamide
5-fluorouracil/epirubicin/cyclophosphamide
Taxane-containing
Paclitaxel monotherapy weekly
Docetaxel monotherapy 3-weekly or weekly
Doxorubicin/taxane (paclitaxel or docetaxel)
Epirubicin/taxane (paclitaxel or docetaxel)
Docetaxel/capecitabine
Paclitaxel/gemcitabine
Paclitaxel/vinorelbine
Paclitaxel/carboplatin
New cytotoxic agents
Ixabepilone
Abraxane (nab-paclitaxel)
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reported outcomes. These should be employed regularly to
help assess the impact of treatment and to monitor symptoms
that demand supportive intervention promptly.
follow-up
 Follow-up after the treatment of local–regional recurrence
may be carried out as for primary breast cancer.
 Patients with MBC must be seen frequently enough to
provide best possible palliation of symptoms and quality of
life, which means on average every 2–3 months if on
endocrine therapy and every one or two cycles of
chemotherapy.
 Finally patients need good quality information and a care plan
outlining all aspects of treatment and care, clarification of the
purpose of different treatments, their side-effects and potential
impact on functional, emotional and social well-being.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
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